Skip to Main Content

Advertisement

Skip Nav Destination

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

Clin Cancer Res (1996) 2 (3): 483–491.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal